Minalrestat and leukocyte migration in diabetes mellitus

Diabetes/Metabolism Research and Reviews

Volumn 19, Issue 3, 2003, Pages 223-231

  Cruz, J W C M ^a   Soto Suazo, M W ^a   Hohman, T C ^b   Akamine, E H ^a   Zorn, T T ^a   Fortes, Z B ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b PFIZER INC   (United States)

Author keywords

Diabetes; Leukocyte migration; Minalrestat

Indexed keywords

ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; CARRAGEENAN; CELL ADHESION MOLECULE; INTERCELLULAR ADHESION MOLECULE 1; LEUKOTRIENE B4; MINALRESTAT; PADGEM PROTEIN; PENTOBARBITAL; POLYOL; TOLRESTAT; ZYMOSAN;

ALLOXAN DIABETES MELLITUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD FLOW VELOCITY; BLOOD VESSEL WALL; CELL INTERACTION; CONTROLLED STUDY; DATA ANALYSIS; DIABETES MELLITUS; DRUG EFFECT; ENDOTHELIUM; ENZYME INHIBITION; GALACTOSEMIA; LEUKOCYTE ADHERENCE; LEUKOCYTE COUNT; LEUKOCYTE MIGRATION; MALE; MICROSCOPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RAT STRAIN; SHEAR RATE; TISSUE INTERACTION; VEIN BLOOD FLOW; VENULE;

ALDEHYDE REDUCTASE; ANIMALS; BLOOD FLOW VELOCITY; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; FRUCTOSE; GALACTITOL; GALACTOSE; GALACTOSEMIAS; HEART RATE; IMIDES; IMMUNOHISTOCHEMISTRY; INTERCELLULAR ADHESION MOLECULE-1; LEUKOCYTE COUNT; LEUKOCYTE ROLLING; MALE; P-SELECTIN; QUINOLONES; RATS; RATS, WISTAR; SORBITOL;

EID: 0037604832     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/dmrr.376     Document Type: Article

References (36)

1. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973 (3rd and last part). (author's transl). Diabet Metab 1977; 3(4): 245-256.
2. Pirart J. Tight glycaemic control prevents diabetic complications. Acta Clin Belg 1995; 50(6): 321-325.
3. Dvornik D. Aldose reductase inhibition. In An Approach to the Prevention of Diabetic Complications. McGraw-Hill: New York, 1987; 69-225.
4. Cameron NE, Cotter MA. Impaired contraction and relaxation in aorta from streptozotocin-diabetic rata: role of polyol pathway. Diabetologia 1992; 35: 1011-1019.
5. Forster HG, Wee PM, Hohman TC, et al. Impairment of afferent arteriolar myogenic responsiveness in the galactosefed rat is prevented by tolrestat. Diabetologia 1996; 39: 907-914.
6. Robison WH Jr, Laver NM, Jacot JL, et al. Diabetic-like retinopathy ameliorated with the aldose reductase inhibitor WAY-121,509. Invest Ophthalm Vis Sci 1996; 37(6): 1149-1156.
7. Garcia-Leme. Cellular functions in inflammation. In J Hormones and Inflammation. CRC Press: Boca Raton, FL, 1989; 192-201.
8. Fortes ZB, Farsky SP, Oliveira MA, et al. Direct vital microscopic study of defective leukocyte-endothelial interaction in diabetes mellitus. Diabetes 1991; 40: 1267-1273.
9. Sannomiya P, Oliveira MA, Anjos-Valotta E, et al. Inhibition of leukocyte-endothelial interactions in diabetes mellitus: role of intercellular adhesion molecule-1 (ICAM-1). J Vasc Res 1996; 33: 6.
10. Sannomiya P, Oliveira MA, Fortes ZB. Aminoguanidine and the prevention of leukocyte dysfunction in diabetes mellitus: a direct microscopy study. Br J Pharmacol 1997; 122: 894-898.
11. Kinoshita JH. Concept of aldose reductase and diabetic cataracts, in Cogan, DG (moderator): aldose reductase and complications of diabetes. Ann Intern Med 1984; 101: 82-91.
12. Cruz JWMC, Oliveira MA, Hohman TC, et al. influence of tolrestat on the defective leukocyte-endothelial interaction in experimental diabetes. Eur J Pharmacol 2000; 391: 163-174.
13. Malamas MS, Hohman TC, Millen J. Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-fluorophenyl)methyl]-6-fluorospiro[isoquinoline-4(1H), 3′-pyrrolidine]-1,2′,3,5′(2H)-tetrone and congeners.1. J Med Chem 1994; 37: 2043-2058.
14. Abelda SM, Smith CW, Ward PA. Adhesion molecules and inflammatory injury. FASEB J 1994; 8: 504-512.
15. Abassi O, Kishimoto JK, McIntire LV, et al. E-selectin supports neutrophil rolling in vitro under conditions of flow. J Clin Invest 1993; 92: 2719-2730.
16. Adams DH, Hubscher SG, Shaw J, et al. Intercellular adhesion molecule-1 on liver allografts during rejection. Lancet 1989; 2: 1122-1125.
17. Jarrett RJ, Keen H, Hardwick C. Instant blood sugar measurement using Dextrostix and a reflectance meter. Diabetes 1970; 19: 724.
18. Guerrant GO, Mass CW. Determination of monosaccharides as aldonitrile O-methyloxamine, alditol and cyclito acetate derivatives by gas chromatography. Anal Chem 1984; 56: 633-638.
19. Cameron NE, Cotter MA, Dines KC, et al. Reversal of defective peripheral nerve conduction velocity, nutritive endoneural blood flow, and oxygenation by a novel aldose reductase inhibitor, WAY-121-509, in streptozotocin-induced diabetic rat. J Diabetes Complications 1996; 10(1): 43-53.
20. 4 and the role of polymorphonuclear leukocytes. Inflammation 1982; 6: 189-200.
21. 4 and inflammatory disease. Agents Actions 1988; 24: 114-119.
22. 3 by the anti-inflammatory agent SC-41930. Agents Actions 1991; 34: 5-7.
23. Pereira MAA, Sannomiya P, Garcia-Leme J. Inhibition of leukocyte chemotaxis by factor in alloxan-induced diabetic rat plasma. Diabetes 1987; 36: 1307-1314.
24. Tomlinson A, Appleton I, Moore AR, et al. Cyclo-oxygenase and nitric oxide synthase isoforms in rat carrageenin-induced pleurisy. Br J Pharmacol 1994; 113: 693-698.
25. Petrone WI, English D, Wong K, et al. Free radicals and inflammation: superoxide-dependent activation of a neutrophil chemotactic factor in plasma. Proc Natl Acad Sci 1980; 77: 1159-1163.
26. Kubes P, Granger DN. Leukocyte-endothelial cell interactions evoked by mast cells. Cardiovasc Res 1996; 32(4): 699-708.
27. Dustin ML, Rothlein R, Bhan AK, et al. Induction by IL-1 and interferon γ: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J Immunol 1986; 137: 245-254.
28. Cosimi AB, Conti D, Delmonico FL, et al. In vivo effects of monoclonal antibody to ICAM-1 (CD54) in nonhuman primates with renal allografts. J Immunol 1990; 144: 4606-4612.
29. Wegner CD, Gundel RH, Reilly P, et al. Intercellular adhesion molecule-1 (ICAM-1) in the pathogenesis of asthma. Science 1990; 247: 456-459.
30. Norris P, Poston RN, Thomas DS, et al. The expression of endothelial leukocyte adhesion molecule-1 (ELAM-1), intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in experimental cutaneous inflammation: a comparison of ultraviolet erythema and delayed hypersensitivity. J Invest Dermatol 1991; 96: 763-770.
31. von Adrian UH, Chambers JD, Mcevoy LM, et al. Two-step model of leukocyte-endothelial cell interaction in inflammation: distinct roles for LECAM-1 and the leukocyte beta-2 integrins in vivo. Proc Natl Acad Sci USA 1991; 88: 7538-7542.
32. von Adrian UH, Hansell P, Chambers JD, et al. L-selectin function is required for beta-2 integrin-mediated neutrophil adhesion at physiologic shear rates in vivo. Am J Phys 1992; 263: H1034-H1044.
33. Crockett-Torabi E. Selectins and mechanisms of signal transduction. J Leukoc Biol 1998; 63: 1-14.
34. Kunkel EJ, Jung U, Bullard DC, et al. Absence of trauma-induced leukocyte rolling in mice deficient in both P-selectin and intercellular adhesion molecule 1. J Exp Med 1996; 183: 57-65.
35. Okayama N, Omi H, Okouchi M, et al. Mechanisms of inhibitory activity of aldose reductase inhibitor, epalrestat, on high glucose-mediated endothelial injury. Neutrophil-endothelial cell adhesion and surface expression of endothelial adhesion molecules. J Diabetes Complications 2002; 16: 321-326.
36. Omi H, Okayama N, Shimizu M, et al. Participation of high glucose concentrations in neutrophil adhesion and surface expression of adhesion molecules on cultured human endothelial cells. Effect of antidiabetic medicines. J Diabetes Complications 2002; 16: 202-208.